Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:RYZB

RayzeBio (RYZB) Stock Price, News & Analysis

RayzeBio logo

About RayzeBio Stock (NASDAQ:RYZB)

Key Stats

Today's Range
$62.49
$62.49
50-Day Range
$62.27
$62.49
52-Week Range
$17.95
$62.51
Volume
N/A
Average Volume
553,592 shs
Market Capitalization
$3.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

Receive RYZB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RayzeBio and its competitors with MarketBeat's FREE daily newsletter.

RYZB Stock News Headlines

Man behind OpenAI makes shocking new bet
Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.
Getting In on This "Macro-Trend"
Andreas Halvorsen's Firm Sells Out of RayzeBio Inc
RYZB Aug 2024 35.000 put
RYZB May 2024 55.000 put
See More Headlines

RYZB Stock Analysis - Frequently Asked Questions

RayzeBio (RYZB) raised $311 million in an initial public offering on Friday, September 15th 2023. The company issued 17,277,600 shares at $18.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that RayzeBio investors own include Apogee Therapeutics (APGE), Broadcom (AVGO), Citigroup (C), Citizens Financial Group (CFG), Cisco Systems (CSCO), Fifth Third Bancorp (FITB) and Intel (INTC).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RYZB
Fax
N/A
Employees
88
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.74 billion
Optionable
Optionable
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:RYZB) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners